• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai , Dec. 21

Ranbaxy Laboratories Ltd, Zydus Cadilla and Aurobindo Pharma have received the approval of the US Food and Drug Administration (USFDA) to market cholesterol lowering drug, Simvastatin, the generic version of Merck's `Zocor'.

Ranbaxy has got the approval to sell the drug in strengths of 5 mg, 10 mg, 20 mg and 40 mg. It has been selling the drug in 80 mg dosage since June.

"We are now in a position to expand our product offerings to include the four additional strengths of Simvastatin. The drug has assumed a prominent position in the management of patients with hypercholesterolemia," said Mr Jim Meehan, Vice-President of Sales and Marketing for Ranbaxy Pharmaceuticals Inc.

Zydus Cadilla and Ranbaxy will market the drug through their US-based subsidiaries, Zydus Pharmaceuticals (USA) Inc and Ranbaxy Pharmaceuticals Inc, respectively.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Volvo shifting Europe truck work to India

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line